BEAT HeartBeam Inc

$BEAT down almost 50% from this week’s high of .95. Madness… it’s trading as if the FDA rescinded their priority designation…. They’re going to give a kickass presentation at the end of the month and reveal trial results that impressed the FDA so much that they responded within 30 days when they had 60 days to respond… 🍾🚀🍾🚀💰💰💰💰

$BEAT Wall Street analysts give HeartBeam, Inc. (BEAT) an average 12-month price target of $3.50, with forecasts ranging from a low of $2.00 to a high of $5.00. This consensus reflects a potential upside of over 700% from its current trading price around $0.44

$BEAT . No one can stop this train. You can get on right now or can scramble and see if the crowd will let you on it next week! Just a matter of time.. tic toc tic tok!!!

$BEAT • The ALIGN-ACS Pilot Study (Full Data Presentation): • The Details: This study evaluated the HeartBeam System in 134 emergency department patients presenting with chest pain across two sites in Belgrade, Serbia. It compared the device directly to standard 12-lead ECGs and final discharge diagnoses to prove its accuracy in detecting heart attacks. • Status: Patient enrollment wrapped up ahead of schedule. The full, highly anticipated data results are scheduled to be presented at the TCT 2026 conference in San Diego (October 31 – November 3, 2026).

$BEAT thinkorswim showing overnight high of .59 and low of .31 after Friday close. Super low volume so it might be nothing but strange that any number of shares can trade at those prices. There’s a pattern this stock surges towards the end of the year. Hope to see $4 again before EOY

$BEAT what are peoples price targets? Mine is short term (2026) we hit $1.20 comfortably. Long term, 3-5$ and beyond.

$BEAT lets be clear here folks. This product has the potential to save lives and impact the world. The next step relies on how positive the data is (which the signs are already pointing to it being extremely good). Once the results are out, there could be strategic partnerships in place to get this product to market. Its extremely exciting and the anticipation is all part of the fun of these volatile stocks. Im happy to invest a decent chunk in this. Lets make some money people. Lets gooooo!😎

$BEAT Inside buying at .80 just a few months ago, plus the possibility of a partner announcement, and FDA trials...........Holding long term

$BEAT Glad yesterday’s rally put this one on my radar. Major catalysts ahead and plenty of upside potential. Extremely bullish! 🎯 $3

$BEAT I believe this stock has the near team ability to reach the previous all time high of over 5 dollars a share. Given the correct news and timing I believe, my personal opinion, that this is archivable sooner than later.

$BEAT has a very quiet 7% share price gain today with a lot more upside potential with the share price in the future. This is a buy and hold long term stock. Swing traders, day traders and penny profit flippers will miss out on huge profits in the future. HOLD LONG NOW & HOLD STRONG NOW!!

$BEAT HeartBeam announced that it received the FDA Breakthrough Device Designation for its HeartBeam System on October 5, 2026. The regulatory agency granted the designation surprisingly quickly, approving the company's request within 30 days of submission—well ahead of the FDA's standard 60-day statutory review window

$BEAT Just so you know, if this were truly a breakthrough device, it wouldn’t be trading at $0.50. The market can be wrong, especially with penny stocks, but it’s usually not that far off.

$BEAT Branislav “brains” has a combined 30 years as a Dr and business man. He will see this through to success and sell. What a nice man. 🥊 knock it home

$BEAT Almost every stock went down Friday but this one didn't. That's a good sign for next week.

$BEAT this company has a market cap of only 22 million, and in the near future it will have sales of hundreds of millions. I say buy it, be patient, forget about it, put it away, and our day will come 

$BEAT not only they will present ALIGN-ACS data at TCT but they will disclose HEADSTART-ACS, study of heart attack detection from 500 patients in Indonesia, in coming weeks. Stay strong, know what you own.

$BEAT will we see an incoming partnership at the end of the month at the conference? I think we will 😎 lets goooo! Giga bullish!

$BEAT it seems obvious the ALIGN-ACS pilot study announcement at the conference is going to be very positive. On October 5, 2026, HeartBeam announced that the FDA had granted its heart attack assessment technology Breakthrough Device Designation. This statement is in the announcement: The designation was supported by earlier proof-of-concept evidence and findings from the 134-patient ALIGN-ACS pilot study.

$BEAT I'm waiting for a partnership deal. Seems like there would be companies interested in partnering with this company in the future after very positive news is released. The potential revenue for this company is very high if all goes well.